WuXi companies may sell units impacted by Biosecure — report
WuXi AppTec and WuXi Biologics are reportedly looking to sell part of their operations that have struggled because of proposed federal legislation that’s targeting the companies on national security...
View ArticleRelay Therapeutics cuts another 10% of company, citing continued streamlining...
Relay Therapeutics is laying off 10% of its staff, or about 30 employees, in an additional round of job cuts after a smaller downsizing in July. A spokesperson for the biotech confirmed the layoffs in...
View ArticleUK government proposes phased rollout of Eli Lilly's weight loss drug
The UK’s publicly funded healthcare system has proposed phasing its rollout of Eli Lilly’s weight loss treatment tirzepatide to ensure those who need it most get early access. An estimated quarter of a...
View ArticleEli Lilly obesity drug shortage ending threatens access to compounded...
Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli Lilly’s popular GLP-1 weight loss drug tirzepatide after the FDA said its...
View ArticleClik here to view.
After $14B exit, Karuna co-founder finds next bet; Ex-Regenxbio CEO Ken Mills...
Andrew Miller Andrew Miller has quickly made his first move after the technology he invented, KarXT, secured an FDA approval last week. The regulator’s nod for Bristol Myers Squibb’s Cobenfy (KarXT)...
View ArticleSanofi sells rare disease drug Enjaymo to Recordati for $825M upfront
Sanofi is offloading its rare autoimmune disease medicine Enjaymo to an Italian pharmaceutical company for $825 million upfront. Recordati, based in Milan, said Friday it will pay up to an additional...
View ArticleBiotech's third quarter was relatively bright — with a few caveats
The weather is getting cooler, but biotech’s recovery is heating up. After a years-long wait-and-see game exhausted many industry insiders, recent signals indicate a mostly promising direction for drug...
View ArticleEditas sells future CRISPR license fees; Plus, news about Oncolytics Biotech
Editas sells future CRISPR licensing fees from Vertex: DRI Healthcare Trust is paying $57 million upfront to the gene editing company in exchange for future licensing payments from Vertex, which struck...
View ArticleJ&J discontinues mid-stage dengue study, citing deprioritization of...
What’s left of Johnson & Johnson’s infectious disease work continues to shrink, after the company announced Friday that it had stopped work on a mid-stage study of its dengue virus antiviral. The...
View ArticleAlnylam agrees to drop patent lawsuit against Moderna over Covid-19 vaccine
Alnylam Pharmaceuticals has agreed to drop its 2023 patent lawsuit against Moderna in a Delaware court following a judge’s ruling in September. In an Oct. 2 filing, Alnylam said the ruling “precludes...
View ArticleRSV vaccines off to a sluggish start in US this season, with volumes behind 2023
This season’s uptake of RSV vaccines in the US has been slower than expected, according to Wall Street analysts tracking prescriptions, and appears to be missing even modest projections for growth...
View ArticleEMA reviews hair loss products following concerns about suicidal thoughts
The European Medicines Agency is looking more closely at medicines used to treat hair loss and a condition caused by an enlarged prostate over concerns about suicidal thoughts. The review encompasses...
View ArticleBARDA doles out $72M to Sanofi, GSK and CSL for bird flu vaccine supply
The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to help fortify the US supply of bird flu vaccine ahead of 2025. The funding was...
View ArticleWuXi companies consider sale of units impacted by Biosecure; J&J, Bayer trim...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
Pfizer targeted by activist, following post-pandemic stumbles — reports
The activist investor Starboard Value has taken a stake in Pfizer, according to media reports, following the drugmaker’s months of lackluster results as it came out of the pandemic and sought the next...
View ArticleClik here to view.
FDA puts Kezar lupus trial on hold after earlier report of patient deaths
Kezar Life Sciences’ autoimmune drug candidate has been put on hold by the FDA after the company said last week that four patients died in a Phase 2b lupus nephritis trial. The patients were in the...
View ArticleUpstream and CAMP4 target $182M, $67M IPOs
Upstream Bio, a mid-stage respiratory drug developer, and CAMP4 Therapeutics, a Phase 1 regulatory RNA startup, have unveiled the targeted price ranges for their initial public offerings. Upstream is...
View ArticleClik here to view.
Judo Bio launches with $100M for kidney-targeted siRNA therapies
The kidney hasn’t always gotten much love from genetic medicine. The organ is vital to our health, but is often viewed as a liability for drug developers. It can flush out otherwise helpful therapies,...
View ArticleOaktree creates third life sciences SPAC, following success with Hims & Hers...
Global investment manager Oaktree is out with its third life sciences-dedicated special purpose acquisition company after previously using blank checks to take public Hims & Hers and Alvotech in...
View ArticleGalapagos investor gets board seat; OnKure completes merger with Reneo
Plus, news about ViiV’s long-acting PrEP and a newly announced merger: Galapagos investor gets board seat: After building up a stake in the struggling Belgian drugmaker, EcoR1 Capital founder Oleg...
View Article